One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 + Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction
Bone Marrow Research · 2011
DOI: 10.1155/2011/385124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone Marrow Research, 2011. Verfasst von Samer Mansour und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division de Cardiologie, Département de Médecine, Centre Hospitalier de l'Université de Montréal (CHUM), 3840, Rue Saint Urbain, Montréal, Québec, Ca…. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133 + hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the initial 20 patients enrolled in the COMPARE-AMI trial, the first double-blind randomized controlled trial comparing the safety, efficacy, and functional effect of intracoronary injection of selected CD133 + cells to placebo following acute myocardial infarction with persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial infarction, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction significantly improved at four months as compared to baseline and remained significantly higher at one year. These data indicate that in the setting of the COMPARE-AMI trial, the intracoronary injection of selected CD133 + stem cells is secure and feasible in patients with left ventricle dysfunction following acute myocardial infarction.
Autor:innen und Institutionen
- Division de Cardiologie, Département de Médecine, Centre Hospitalier de l'Université de Montréal (CHUM), 3840, Rue Saint Urbain, Montréal, Québec, Canada H2W 1T8.
Zitieren
APA
Mansour, S., Roy, D. C., Bouchard, V., Stevens, L. M., Gobeil, F., Rivard, A., Leclerc, G., Reeves, F., & Noiseux, N. (2011). One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 + Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Research. https://doi.org/10.1155/2011/385124
Vancouver
Mansour S, Roy DC, Bouchard V, Stevens LM, Gobeil F, Rivard A, et al. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 + Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Research. 2011. doi:10.1155/2011/385124
BibTeX
@article{Mansour2011,
author = {Mansour, Samer and Roy, Denis-Claude and Bouchard, Vincent and Stevens, Louis Mathieu and Gobeil, Francois and Rivard, Alain and Leclerc, Guy and Reeves, François and Noiseux, Nicolas},
title = {One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 + Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction},
journal = {Bone Marrow Research},
year = {2011},
doi = {10.1155/2011/385124}
}
EUVIMED